Table 3 Dose modification criteria, acute neuropathy assessment tools and incidence of acute neuropathy
Study author | Starting dose of oxaliplatin | Dose modification criteria | Toxicity assessment tool | Acute neurotoxicity |
|---|---|---|---|---|
Argyriou [17] | 85Â mg/m2 | -Oxaliplatin: 30% reduction for persistent or temporary (at least 14Â days) painful paresthesia, dysesthesia or functional impairment -Grade 3 persisted with 30% dose reduction, OXA omitted | -NCI-CTC v3.0 -NCS | Acute neuropathy (85.9%) |
Argyriou [32] | NR | -Oxaliplatin: 30% reduction for persistent or temporary (at least 14 days) painful paresthesia, dysesthesia or functional impairment -Grade 3 persisted with 30% dose reduction, OXA omitted | -TNSc -NCI-CTC | Acute cold induced perioral dysesthesia (89.3–98.4%) and pharyngolaryngeal dysesthesia (91.7–98.3%) |
Davidov [38] | 85 mg/m2 | -Oxaliplatin: 25% reduction for persistent paresthesia between cycles. Second 25% reduction if no improvement. | -WHO toxicity criteria | Acute neuropathy (58.3%), prolonged infusion (17–23.2%), |
Diaz-Rubio [11] | 130 mg/m2 | −25% reduction for NCI grade 3 neutropenia, thrombocytopenia, peripheral neurotoxicity, or grade 2 renal toxicity. 50% reduction for grade 4 neutropenia, thrombocytopenia or grade 3 renal toxicity | -NCI-CTC (National Cancer Institute Common Toxicity Criteria) criteria | Laryngopharyngeal dysesthesia, and severe dyspnea 1(4%) |
Land [36] | 85Â mg/m2 | -Oxaliplatin: dose reduced for grade2 toxicity persisted b/n cycles or any grade 3 toxicity. Dose termination: persistent grade 3 or grade 4 toxicity | -FACT (Functional Assessment of Cancer Therapy) -OSNS (Oxaliplatin Specific Neurotoxicity Scale) | Acute neurotoxicity (68%) |
Levi [15] | 25 mg/m2 | NR | -WHO haematological, skin, mucosal, & hair toxicity. Symptomatic neurological toxicity grading | Paresthesia of finger and toes in cycle Grade 1–2 (58%) |
Ravaioli [33] | 130Â mg/m2 | NR | -WHO toxicity criteria used | Acute neuropathy (20%) |
Rothenberg [8] | 85 mg/m2 | -Dose of oxaliplatin reduced by 24% for grade 3/4 febrile neutropenia, thrombocytopenia, nausea vomiting, diarrhoea and grade4 stomatitis. Discontinue for grade 3/4 allergic reaction. | -NCI-CTC v2.0 | Acute, cold-sensitive paresthesias: all grades (58%) & grades 3–4: (7%) |
Schmoll [37] | 130 mg/m2 | -Oxaliplatin: 23% reduction for grade 3/4 nausea or vomiting, grade 4 stomatitis, and for paresthesias with pain or functional impairment lasting for more than 7 days, or paresthesias with pain persisting between cycles | -NCI-CTC v3.0 | Grades 2–4 neuropathy on day one. |
Storey [25] | 130 mg/m2 | -Oxaliplatin: Infusion prolonged for 4 or 6 h after acute, jelly legs, pseudolaryngospasm and severe laryngeal dysaesthesia. | -NCI-CTC v3.0 | Acute neuropathy (94%), prolonged infusion (22%), dose reduction (14.5%), treatment delay (2%), treatment cessation (13%) & function impairment function /grade2–4 (43%) |